ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > AGM @ 10AM of Today EST

<< Previous

Bullboard Posts

Next >>

Post by G1945Von Oct 23, 2024 11:44am

159 Views

Post# 36278635

AGM @ 10AM of Today EST

It lasted no more than 10 minutes. No new information was provided, and there was no discussion at all. There was no new presentation. I questioned the missing Cohort #5 of Phase 1. I did not receive a response. It ended pretty abruptly.

G1945V

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments